

1st August, 2018

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sir,

Sub: Clarification on Press Release titled “Wockhardt sets up its first manufacturing and R&D unit in Middle East”

This refers to your E-mail dated 1st August, 2018 seeking clarification on Press Release, titled “Wockhardt sets up its first manufacturing and R&D unit in Middle East” submitted to Stock Exchanges on 29th July, 2018.

In this regard, we would like to inform you that Wockhardt with an aim to grow and expand its international presence in Pharmaceutical manufacturing inaugurated its state-of-the-art manufacturing facility in JAFZA, Dubai, UAE in July 2018 for production and packaging of sterile dry powder injections for its novel New Chemical Entities (NCEs) in breakthrough Anti-infectives.

Wockhardt has 5 breakthrough NCEs that have been accorded coveted Qualified Infectious Disease Product (QIDP) status by US FDA and are in advanced stages of clinical trials. Wockhardt conducted extensive studies for identifying a region in Middle East to establish strong manufacturing presence for its advanced patented drugs that would cater to the global market.

The construction of the facility is complete with a cost of about USD 30 Million which has been funded through internal accruals and borrowings. The facility will work on exhibit batches and will be offered for inspections by the regulators at an appropriate time and upon approval will be commissioned for commercial production.

Kindly take the same on your records.

For **Wockhardt Limited**



Narendra Singh
Company Secretary

